March 2008 PBAC Outcomes - Deferrals

PDF Printable version this page (PDF 19 KB)

table showing deferrals made by the PBAC - March 08

Drug and Form

Drug Use and Type

Listing Requested by Sponsor

PBAC Outcome and Comment

ALENDRONATE SODIUM with COLECALCIFEROL, tablet, equivalent to 70 mg alendronic acid with 140 micrograms colecalciferol, Fosamax Plus® 70/140
Merck Sharp and Dohme (Australia) Pty Ltd 

Minor submission
Osteoporosis Authority required (streamlined) listing similar to Fosamax Plus® (alendronic acid 70 mg with colecalciferol 70 micrograms). The PBAC deferred a final decision pending registration of the product by the Therapeutic Goods Administration.
Sponsor’s comments The sponsor had no comment.
MELOXICAM, tablets, 7.5 mg and 15 mg and capsules, 7.5 mg and 15 mg, Mobic® 
Boehringer Ingelheim Pty Ltd

Minor submission
Anti-inflammatory agent Restricted benefit listing for symptomatic relief of rheumatoid arthritis. The PBAC deferred a recommendation on this item, noting that it had never formally assessed meloxicam for this use.
Sponsor’s comments The sponsor had no comment